Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

被引：77

作者：

Cilloni, Daniela ^{[1
]}

Messa, Francesca ^{[1
]}

Arruga, Francesca ^{[1
]}

Defilippi, Ilaria ^{[1
]}

Gottardi, Enrico ^{[1
]}

Fava, Milena ^{[1
]}

Carturan, Sonia ^{[1
]}

Catalano, Renata ^{[1
]}

Bracco, Enrico ^{[1
]}

Messa, Emanuela ^{[1
]}

Nicoli, Paolo ^{[1
]}

Diverio, Daniela ^{[2
]}

Sanz, Miguel A. ^{[3
]}

Martinelli, Giovanni ^{[4
]}

Lo-Coco, Francesco ^{[5
]}

Saglio, Giuseppe ^{[1
]}

机构：

[1] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

[2] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy

[3] Hosp Univ La Fe, Dept Med Biopathol, Valencia, Spain

[4] Univ Bologna, Seragnoli Inst, Dept Hematol, Bologna, Italy

[5] Univ Tor Vergata, Dept Biopathol, Rome, Italy

来源：

HAEMATOLOGICA | 2008年 / 93卷 / 06期

关键词：

WT1; minimal residual disease; acute leukemia; RQ-PCR;

D O I：

10.3324/haematol.12165

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The Wilms' tumor gene WT1 is a reliable marker for minimal residual disease assessment in acute leukemia patients. The study was designed to demonstrate the potential use of WT1 to establish quality of remission in acute leukemia patients for early identification of patients at high risk of relapse. A prospective study based on a quantitative Real-Time PCR (TagMan) assay in 562 peripheral blood samples collected from 82 acute leukemia patients at diagnosis and during follow-up was established.The evaluation of WT1 in peripheral blood samples after induction chemotherapy can distinguish the continuous complete remission patients from those who obtain only an "apparent" complete remission and who could relapse within a few months. WT1 helps identify patients at high risk of relapse soon after induction chemotherapy allowing post-induction therapy in high risk patients to be intensified.

引用

页码：921 / 924

页数：4

共 24 条

[21] Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia
Sugiyama, H
[J]. LEUKEMIA & LYMPHOMA, 1998, 30 (1-2) : 55 - 61
[22] Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease -: Report of the BIOMED-1 Concerted Action:: Investigation of minimal residual disease in acute leukemia
van Dongen, JJM
Macintyre, EA
Gabert, JA
Delabesse, E
Rossi, V
Saglio, G
Gottardi, E
Rambaldi, A
Dotti, G
Griesinger, F
Parreira, A
Gameiro, P
Diáz, MG
Malec, M
Langerak, AW
San Miguel, JF
Biondi, A
[J]. LEUKEMIA, 1999, 13 (12) : 1901 - 1928
[23] Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia
Venditti, A
Buccisano, F
Del Poeta, G
Maurillo, L
Tamburini, A
Cox, C
Battaglia, A
Catalano, G
Del Moro, B
Cudillo, L
Postorino, M
Masi, M
Amadori, S
[J]. BLOOD, 2000, 96 (12) : 3948 - 3952
[24] Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia
Weisser, M
Kern, W
Rauhut, S
Schoch, C
Hiddemann, W
Haferlach, T
Schnittger, S
[J]. LEUKEMIA, 2005, 19 (08) : 1416 - 1423

← 1 2 3 →